Muscarinic Acetylcholine Receptor
Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action
Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.
Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy
Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics